TROPION-Breast05
Tests whether Dato-DXd plus a PD-L1 blocker beats today's immunotherapy-chemotherapy standard.
TROPION-Breast05 has a three-arm design, with readout expected 2026-27. Together with ASCENT-04 will define ADC+IO first-line therapy.
Setting
First-line PD-L1+ metastatic TNBC: Dato-DXd ± durvalumab vs pembrolizumab + chemotherapy
Phase
Phase 3
Sponsor
AstraZeneca / Daiichi Sankyo
Registry
Enrolled
625
Replication
Ongoing; no results.